All In Biotech

Drug Trial Radar · NCT06710132

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

184

Actual

Start

Jan 29, 2025

Primary completion

Dec 23, 2027

Study completion Dec 23, 2027

Sponsor

Sponsor type
Industry
Collaborators
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; Merck KGaA, Darmstadt, Germany
First posted
Nov 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that may be conducted in parallel. * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Gastric Cancer (Substudy GC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC).

Conditions

  • Solid Tumors
  • Gastric Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Pancreatic Cancer
  • Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

  • M9140Drug

    All participants will receive 2.8 milligram per kilogram (mg/kg) M9140 intravenously (i.v.) every 3 weeks (q3w) on Day 1 of consecutive 21-day cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Substudies GC/NSCLC/PDAC: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by InvestigatorsTime frame: Time from first study treatment to (planned) final assessment at approximately 48 months

Locations

81 sites in 10 countries. Site status is shown where the registry gives one.

  • University of California - Los Angeles - 300208353

    Santa Monica, California

  • Providence Medical Foundation

    Santa Rosa, California

  • Georgetown University - Lombardi Comprehensive Cancer Center - 1134847

    Washington D.C., District of Columbia

  • D&H Cancer Research Center

    Margate, Florida

  • Prisma Health Cancer Institute, ITOR, CRU

    Greenville, South Carolina

  • Baptist Cancer Center

    Memphis, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • NEXT Virginia

    Fairfax, Virginia

  • Flinders Medical Centre

    Bedford Park, Australia

  • Nepean Cancer Care Centre

    Kingswood, Australia

  • Mater Misericordiae Ltd - PARENT

    South Brisbane, Australia

  • Macquarie University Hospital - PARENT

    Sydney, Australia

  • Ordensklinikum Linz Krankenhaus der Elisabethinen Linz - Pneumology

    Linz, Austria

  • LKH - Universitätsklinikum der PMU Salzburg - Innere Med III/Hämatologie und Onkologie

    Salzburg, Austria

  • Medical University of Vienna - Department of Internal Medicine

    Vienna, Austria

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangzhou, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Xiangya Hospital, Central South University

    Changsha, Hu'nan, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine - Department of Oncology Surgery

    Hangzhou, Zhejiang, China

  • Institut Bergonié - Service d'Oncologie Médicale

    Bordeaux, France

  • Centre Georges François Leclerc - Unité de Phase I

    Dijon, France

  • Centre Oscar Lambret - cancerologie generale

    Lille, France

  • Hopital Albert Calmette - CHU Lille - CHU Lille - Institut Coeur Poumon

    Lille, France

  • Hôpital Européen Georges Pompidou - Hématologie Oncologie

    Paris, France

  • Hôpital Saint-Antoine - Oncologie Médicale

    Paris, France

  • ICO - Site René Gauducheau - Service d'Oncologie medicale

    Saint-Herblain, France

  • Hôpital Foch - Service d'Oncologie Médicale

    Suresnes, France

  • Institut Claudius Regaud - Service d'oncologie médicale

    Toulouse, France

  • Institut Gustave Roussy - Pathologie Thoracique

    Villejuif, France

  • Charité - Campus Charité Mitte - Charité Comprehensive Cancer Center

    Berlin, Germany

  • Krankenhaus Nordwest GmbH - Neurologische Klinik

    Frankfurt am Main, Hesse, Germany

  • St. Josef-Hospital im Katholischen Klinikum Bochum - Haematologie, Onkologie und Palliativmedizin

    Bochum, North Rhine-Westphalia, Germany

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - I. Medizinische Klinik Gastroenterologie u Hepato.

    Mainz, Rhineland-Palatinate, Germany

  • Universitaetsklinikum Carl Gustav Carus TU Dresden - Medizinische Klinik I

    Dresden, Saxony, Germany

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.